April 29, 2003
Proceedings of the National Academy of Sciences of the United States of America
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
PA-Binding Studies:
PA binding to CHO-R1.1 cells that expressed CMG2489-EGFP or ATR/TEM8 sv2-EGFP was assessed by flow-cytometric analysis; 106 cells of each type were incubated with 50 nM PA (1 h, 4C), washed with PBS, incubated with a polyclonal PA-specific rabbit antiserum (9) (1:500 dilution, 1 h, 4C), washed with PBS again, and then incubated with an allophycocyanin-conjugated anti-rabbit antibody (Molecular Probes; 1:2,000 dilution, 1 h, 4C). ELISAs were performed by binding 0.3 g of PA83 (List Biological Laboratories, Campbell, CA)/100 l of TBS in a well of a MaxiSorp plate (Nalge). Samples were then treated with TBST solution (TBS containing 3% BSA and 0.05% Tween 20), washed with TBST, and incubated with 0300 ng of purified CMG2VWA/I-MycHis/100 l TBST in the absence or presence of 1 mM MgCl2, MnCl2, CaCl2, or ZnCl2. The samples were then washed with TBST and incubated with a horseradish peroxidase-conjugated anti-His antibody (1:2,000 dilution; Santa Cruz Biotechnology). All incubations for ELISAs were performed for 1 h at room temperature. The levels of bound antibody were then measured by using Supersignal ELISA Pico chemiluminescent substrate (Pierce) and a luminometer (Victor V, Wallac).
Intoxication Assays:
Cell viability assays (WST-1 assay; Roche Molecular Biochemicals) were performed in triplicate by incubating 5,000 cells of each type for 30 h with 2 1010 M LFN-diptheria toxin A chain (DTA) and varying concentrations of PA (1012 to 108 M; List Biological Laboratories) or no PA (100% viability control). The inhibition assays were performed as above with different amounts of CMG2VWA/I-MycHis (01,000 ng/100 l) added to 109 M PA and 1010 M LFN-DTA before this mixture was added to cells. The IC50 was determined by regression analysis (prism, GraphPad, San Diego).